Multiple sclerosis (MS) is currently one of the main causes of disability in the young and currently has no cure till date. There have been advances in the therapeutic options for patients with multiple sclerosis. Treatment is aimed at disease modifying and symptoms management. Glatiramer and interferons are the first line drugs used for the treatment. Both drugs alter the short-term course of MS. Currently disease modifying therapies (DMTs) are available for mostly relapsing forms of MS. They decrease the clinical episodes of inflammation, new magnetic resonance imaging (MRI) lesions and decrease the progression of disability. Accurate diagnosis helps in proper approach to treatment and it relies on a combination of clinical history, neurological examination and paraclinical testing such as MRI and sometimes cerebrospinal fluid analysis.